Channel
@hematologyreview
On this record: Topic · Growth · Engagement · Reactions · Posts · Citations · Cite this entry
1,893subscribers
+34 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of 1,000–3,162.
| Telegram ID | -1001920046621 |
|---|---|
| Type | Channel |
| Username | @hematologyreview |
| Created | Between 1 April 2023 and 31 October 2023 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 7 August 2026 |
| Last confirmed live | 9 October 2026 |
| Measurements held | 14 |
| Confirmed unchanged | 1 time, most recently 9 October 2026 |
| On Telegram | t.me/hematologyreview |
Education — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 16 September 2026 and assigned it the closest of 31 fixed categories, at 95% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 9 Oct 2026, 00:41 | 1,893 | +13 |
| 2 Oct 2026, 16:37 | 1,880 | +20 |
| 16 Sept 2026, 07:37 | 1,860 | -1 |
| 12 Sept 2026, 04:21 | 1,861 | +4 |
| 7 Sept 2026, 19:41 | 1,857 | -1 |
| 2 Sept 2026, 18:24 | 1,858 | -4 |
| 27 Aug 2026, 12:53 | 1,862 | +2 |
| 24 Aug 2026, 14:56 | 1,860 | -2 |
| 20 Aug 2026, 22:53 | 1,862 | +2 |
| 17 Aug 2026, 17:44 | 1,860 | -1 |
| 14 Aug 2026, 16:38 | 1,861 | +1 |
| 11 Aug 2026, 04:41 | 1,860 | +1 |
| 7 Aug 2026, 20:47 | 1,859 | no change |
| 7 Aug 2026, 19:24 | 1,859 | first reading |
19 posts held, back to 8 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 19 posts for this entry, the most recent from 7 August 2026. An engagement rate over an empty window would be a number about nothing.
38 reactions across 13 posts, in 3 distinct kinds. The most used accounts for 78.9% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 30 | 78.9% | |
| 👍 | 6 | 15.8% | |
| 💔 | 2 | 5.26% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 13 of the 19 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 38 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 19 most recent posts we hold, published 8 July 2026 to 7 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Drugs associated with autoimmune hemolytic anemia and/or a positive direct antiglobulin test (DAT; Coombs test) #Drug #AIHA #autoimmune_Hemolytic_Anemia #DAT کانال مرور هماتولوژی 🩸 https://t.me/hematologyreview کانال CoagLab 🩸 https://t.me/coaglab
Signed Arash
Partial list of medicines and other substances thought to be unsafe or safe in individuals with G6PD deficiency #Drug #G6PD کانال مرور هماتولوژی 🩸 https://t.me/hematologyreview کانال CoagLab 🩸 https://t.me/coaglab
Signed Arash
Platelet transfusion in patients with TTP (August 2026) Thrombotic thrombocytopenic purpura (TTP) is a life-threatening condition with thrombocytopenia and microvascular thrombosis; bleeding is rare but can occur. Platelet transfusions are perceived to worsen thrombotic risk, but this is not well supported. In a retrospective study of 693 patients with newly diagnosed TTP in which 14 percent received platelet transf…
👍3❤1
Signed Arash
Laboratory investigation and clinical management of acquired coagulation factor inhibitors: A joint British Society for Haematology and United Kingdom Haemophilia Centre Doctors' Organisation Guideline https://onlinelibrary.wiley.com/doi/10.1111/bjh.70200 #Acquired #Hemophilia #Acquired_Hemophilia #Coagulation_Factor کانال مرور هماتولوژی 🩸 https://t.me/hematologyreview کانال CoagLab 🩸 https://t.me/coaglab
❤1
Signed Arash
Acquired hemophilia A (and other acquired coagulation factor inhibitors) #Acquired #Hemophilia #Acquired_Hemophilia #Coagulation_Factor کانال مرور هماتولوژی 🩸 https://t.me/hematologyreview کانال CoagLab 🩸 https://t.me/coaglab
Signed Arash
Duration of lenalidomide maintenance in standard-risk myeloma (July 2026) Patients with newly diagnosed, standard-risk multiple myeloma (MM) not undergoing autologous hematopoietic cell transplantation (HCT) commonly receive induction followed by lenalidomide-based maintenance until progression (indefinite maintenance). In a randomized trial in such patients, indefinite versus two years of maintenance lenalidomide f…
❤3
Signed Arash
Pirtobrutinib, venetoclax, and rituximab in relapsed chronic lymphocytic leukemia (July 2026) Combinations that target BTK and BCL2 are highly effective, fixed-duration treatment options for chronic lymphocytic leukemia (CLL). In a randomized trial in patients with relapsed or refractory CLL, primarily after a covalent BTK inhibitor therapy, the addition of the noncovalent BTK inhibitor pirtobrutinib to fixed-durati…
❤2
Signed Arash
Evaluation of the peripheral blood smear #CBC #PBS کانال مرور هماتولوژی 🩸 https://t.me/hematologyreview کانال CoagLab 🩸 https://t.me/coaglab
💔2❤1👍1
Signed Arash
Evaluating smudge cells on the peripheral blood smear Smudge cells are mature-appearing small lymphocytes that appear flattened or smudged on the slide; the mechanism involves vulnerability to distortion during smear preparation. Normally these cells represent <2% of nucleated cells in a blood smear; this percentage can be increased if the smear has been prepared from blood that has been sitting for ≥12 hours, in wh…
❤2
Signed Arash
Clinical report on iron deficiency in children (June 2026) A new clinical report on prevention, diagnosis, and treatment of iron deficiency in children has been published by the American Academy of Pediatrics and American Society of Pediatric Hematology and Oncology. A key update is to use higher ferritin thresholds for diagnosing iron deficiency (≤20 ng/mL [45 pmol/L] for age ≥9 months through <11 years, and ≤30 ng…
❤3
Signed Arash
Subcutaneous isatuximab in multiple myeloma (July 2026) The anti-CD38 monoclonal antibody isatuximab is widely used for the treatment of multiple myeloma. While initial trials evaluating its efficacy used intravenous (IV) weight-based dosing, fixed-dose subcutaneous (SC) isatuximab has demonstrated similar efficacy and lower rates of infusion-related reactions when compared with IV administration in a randomized tri…
❤3
Signed Arash
🩸 LearnHaem یکی از بهترین منابع رایگان آموزش هماتولوژی است که مطالب را بهصورت ساده، تصویری و کاربردی ارائه میکند. https://www.learnhaem.com این سایت شامل آموزش بیماریهای خونی، اسمیر خون محیطی، مغز استخوان، انعقاد، انتقال خون، کیسهای بالینی و آزمونهای آموزشی است و برای دانشجویان پزشکی، رزیدنتها و علاقهمندان به هماتولوژی منبعی ارزشمند محسوب میشود. https://www.learnhaem.com کانال مرور هماتولوژی 🩸 https://t.m…
❤10👍1
Signed Arash
Showing the 12 most recent of 19 posts we hold for @hematologyreview. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 9 October 2026 — this entry's latest reading, not the date you are reading this.
“Hematology Review” (@hematologyreview), 1,893 subscribers as measured 9 October 2026. Telegram Register, tgregister.com/channel/hematologyreview.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.